SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease,
affecting approximately one-quarter of the global population, and has become a world public …

The endoplasmic reticulum (ER) is an intracellular organelle that fosters the correct folding
of linear polypeptides and proteins, a process tightly governed by the ER‐resident enzymes …

Background Empagliflozin has been reported to protect endothelial cell function, regardless
of diabetes status. However, the role of empagliflozin in microvascular protection during …

The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney
disease (DKD) remains one of the leading long-term complications of T2D. Several lines of …

Non-alcoholic fatty liver disease (NAFLD) is an 'umbrella'term, comprising a spectrum
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …

A rapidly increasing incidence of non-alcoholic fatty liver disease (NAFLD) is noted
worldwide due to the adoption of western-type lifestyles and eating habits. This makes the …

The metabolic associated fatty liver disease (MAFLD) is a public health challenge, leading to
a global increase in chronic liver disease. The respiratory exposure of silica nanoparticles …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide. It is strongly associated with obesity, type 2 diabetes (T2DM), and other …

Mitochondria are well known as the centre of energy metabolism in eukaryotic cells.
However, they can not only generate ATP through the tricarboxylic acid cycle and oxidative …